Allogene Therapeutics, Inc. Payments to Acquire Equity Method Investments
Allogene Therapeutics, Inc. (ALLO) reported Payments to Acquire Equity Method Investments of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquityMethodInvestments · last filed 2024-03-14
- Allogene Therapeutics, Inc. payments to acquire equity method investments for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Allogene Therapeutics, Inc. payments to acquire equity method investments for the quarter ending 2022-09-30 was $0.00.
- Allogene Therapeutics, Inc. payments to acquire equity method investments for the quarter ending 2022-06-30 was $0.00.
- Allogene Therapeutics, Inc. payments to acquire equity method investments for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Allogene Therapeutics, Inc. payments to acquire equity method investments for fiscal 2023 was $0.00.
- Allogene Therapeutics, Inc. payments to acquire equity method investments for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Allogene Therapeutics, Inc. payments to acquire equity method investments for fiscal 2021 was $17.71M.
- Allogene Therapeutics, Inc. payments to acquire equity method investments for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
| Period end | Payments to Acquire Equity Method Investments 1 month | Payments to Acquire Equity Method Investments 3 month | Payments to Acquire Equity Method Investments 6 month | Payments to Acquire Equity Method Investments 9 month | Payments to Acquire Equity Method Investments 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-14 | ||||
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $0.00 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $0.00 10-Q · filed 2022-11-02 | $1.77M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $1.77M derived: sum of 3 quarters · filed 2024-03-14 | $1.77M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 | $1.77M derived: sum of 2 quarters · filed 2024-03-14 | $1.77M derived: sum of 3 quarters · filed 2024-03-14 | $1.77M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | $1.77M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $1.77M derived: sum of 2 quarters · filed 2024-03-14 | $1.77M derived: sum of 3 quarters · filed 2024-03-14 | $17.71M 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $15.94M 10-Q · filed 2022-11-02 | $15.94M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $15.94M 10-Q · filed 2022-08-09 | $15.94M derived: sum of 3 quarters · filed 2024-03-14 | $15.94M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-03-31 | $15.94M 10-Q · filed 2022-05-04 | $15.94M derived: sum of 2 quarters · filed 2024-03-14 | $15.94M derived: sum of 3 quarters · filed 2024-03-14 | $15.94M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $0.00 10-K/A · filed 2024-03-14 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-05 | ||||
| 2019-12-31 | $5.08M 10-K · filed 2022-02-23 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |